1. Search Result
Search Result
Results for "

Rituximab (anti-CD20)

" in MedChemExpress (MCE) Product Catalog:

4

阻害剤およびアゴニスト

4

阻害性抗体

製品番号 製品名 Target 研究分野 構造式
  • HY-P9913A
    Rituximab (anti-CD20)
    10+ Cited Publications

    CD20 Inflammation/Immunology Cancer
    Rituximab (anti-CD20) is an anti-CD20 chimeric monoclonal antibody used to treat certain autoimmune diseases and types of cancer .
    Rituximab (anti-CD20)
  • HY-P9913
    Rituximab
    10+ Cited Publications

    Anti-Human CD20 type I, Chimeric Antibody; HSDB 7455; IDEC-C2B8

    Radionuclide-Drug Conjugates (RDCs) CD20 Inflammation/Immunology Cancer
    Rituximab is an anti-CD20 chimeric monoclonal antibody used for research of certain autoimmune diseases and cancer.
    Rituximab
  • HY-P991225

    Fc Receptor (FcR) CD20 Inflammation/Immunology Cancer
    BI-1206 is a recombinant and antagonistic human monoclonal antibody targeting FcγRIIB (CD32B). BI-1206 can block CD20 internalization induced by Rituximab (HY-P9913) itself or combined with others including Ibrutinib (HY-10997), Venetoclax (HY-15531), and CHOP. BI-1206 can enhance or recover the activity of Rituximab or other anti-CD20 monoclonal antibodies. BI-1206 has cytolytic activity against malignant B cells. BI-1206 can be studied for cancer research such as mantle cell lymphoma (MCL) .
    BI-1206
  • HY-P991902

    CD20 Cancer
    NAV006 is an anti-CD20 antibody variant of Rituximab (HY-P9913) with a Kd of 30.5 nM to CD20. NAV006 exhibits reduced interaction with CA125 and demonstrates enhanced antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) activity. NAV006 displays antitumor activity against lymphoma and can be used in research on non-Hodgkin lymphoma .
    NAV006

オンラインお問い合わせ

入力情報は安全に管理されます. 必須入力項目.

タイトル

 

国或いは地域 *

お名前 *

 

組纖名 *

デパートメント *

     

メールアドレス *

 

製品名 *

製品番号

 

カスタマ需要量 *

電話番号 *

     

必ず会社名を記載ください。個人への返信は行いません。

備考

バルクお問い合わせ

Inquiry Information

製品名:
製品番号:
数量:
MCE 日本正規代理店: